These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30056037)

  • 1. Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus.
    Kuranov SO; Tsypysheva IP; Khvostov MV; Zainullina LF; Borisevich SS; Vakhitova YV; Luzina OA; Salakhutdinov NF
    Bioorg Med Chem; 2018 Aug; 26(15):4402-4409. PubMed ID: 30056037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
    Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.
    Xing J; Li Q; Zhang S; Liu H; Zhao L; Cheng H; Zhang Y; Zhou J; Zhang H
    Chem Biol Drug Des; 2014 Sep; 84(3):364-77. PubMed ID: 24674599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Biological Evaluation, and Molecular Docking of (R)-2-((8-(3-aminopiperidin-1-yl)-3-methyl-7-(3-methylbut-2-en-1-yl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors.
    Ran Y; Pei H; Shao M; Chen L
    Chem Biol Drug Des; 2016 Feb; 87(2):290-5. PubMed ID: 26426933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M; Gupta M; Singh D; Kumar M; Kaur P
    Chem Biol Drug Des; 2013 Aug; 82(2):156-66. PubMed ID: 23581745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4.
    Lin K; Cai Z; Wang F; Zhang W; Zhou W
    Chem Pharm Bull (Tokyo); 2013; 61(4):477-82. PubMed ID: 23358258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of azobicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes.
    Cho TP; Long YF; Gang LZ; Yang W; Jun LH; Yuan SG; Hong FJ; Lin W; Liang GD; Lei Z; Jing LJ; Shen GA; Hong SG; Dan W; Ying F; Ke YP; Ying L; Jun F; Tai MX
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3565-8. PubMed ID: 20488702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X; Han L; Zhou J; Zhang H; Li Q
    Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors.
    Li N; Wang LJ; Jiang B; Guo SJ; Li XQ; Chen XC; Luo J; Li C; Wang Y; Shi DY
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2131-2135. PubMed ID: 29773502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
    Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
    Li Q; Han L; Zhang B; Zhou J; Zhang H
    Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.
    Deng X; Shen J; Zhu H; Xiao J; Sun R; Xie F; Lam C; Wang J; Qiao Y; Tavallaie MS; Hu Y; Du Y; Li J; Fu L; Jiang F
    Bioorg Med Chem; 2018 Feb; 26(4):903-912. PubMed ID: 29373269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators.
    Fang Y; Zhang S; Wu W; Liu Y; Yang J; Li Y; Li M; Dong H; Jin Y; Liu R; Yang Z
    Bioorg Chem; 2020 Jan; 94():103390. PubMed ID: 31662212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
    Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
    Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.